Tim Inderhees

Tim Inderhees

Auto-generated profile, based on publicly available information

Tim Inderhees

Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
Christian-H HeegerChristian-H Heeger
Christian-H Heeger
SPSorin Stefan Popescu
Sorin Stefan Popescu
TITim Inderhees
Tim Inderhees
NNNoemi Nussbickel
Noemi Nussbickel
CECharlotte Eitel
Charlotte Eitel
RTRoland Richard Tilz
Roland Richard Tilz
Catheter ablation with a cryoballoon (CB) provides effective and durable pulmonary vein (PV) isolation (PVI) associated with encouraging clinical outcome data. The novel POLARx CB incorporates unique features, which may translate into improved safety, efficacy, and outcomes. The ICE-AGE-1 study aimed to assess the efficacy, safety, and 1-year clinical follow-up of the POLARx CB in comparison to the Arctic Front Advance Pro CB (AF-CB4). A total of 103 consecutive patients with paroxysmal or persistent atrial fibrillation (AF) who underwent POLARx-based PVI (POLARx group) were prospectively enrolled and were compared to 102 consecutive patients previously treated with the AF-CB4 (AF-CB4 group). The mean age was 68.7 ± 10.2 (POLARx) and 65.7 ± 12 (AF-CB4, P = 0.0551) years. A total of 412 (POLARx) and 404 (AF-CB4) PVs were identified. All PVs, except for one PV in the POLARx group, were successfully isolated. A significant difference regarding the mean minimal CB temperature reached using the POLARx CB (−56.1 ± 8.3°C) and AF-CB4 (−46.9 ± 10.1°C) was observed (P < 0.0001). Real-time PVI was visualized in 71% of PVs in the POLARx group and 46% of them in the AF-CB4 group (P < 0.001). The mean procedure time was comparable: 54.5 ± 17.1 min for POLARx and 59.4 ± 18.6 min for AF-CB4 (P = 0.0509). No differences were observed in terms of periprocedural complications. There were comparable rates in freedom of AF or atrial tachycardia recurrence after 12 months, beyond a 90-day long blanking period: 78.9% in the POLARx group vs. 77.2% in the AF-CB4 group (P = 0.804). The novel POLARx CB showed similar safety, efficacy, and 1-year recurrence-free survival rates compared to the AF-CB4. A higher rate of real-time electrical PV recordings and significantly lower balloon temperatures were observed using the POLARx as compared to AF-CB4.

4 June 2025 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
FFFabian Falkenbach
Fabian Falkenbach
LHLukas Hohenhorst
Lukas Hohenhorst
MKMykyta Kachanov
Mykyta Kachanov
TITim Inderhees
Tim Inderhees
DBDirk Beyersdorff
Dirk Beyersdorff
LBLars Budäus
Lars Budäus